ERBB2 and neoplasm: The ability of our vaccine to trigger Her2-specific antibody responses has significant therapeutic implications, as a broader repertoire of Her2-reactivities and antibody isotypes may lead to enhanced tumor specific antibody dependent cellular cytotoxicity or enhanced antibody-induced perturbation of Her2 signaling.